Mr. Norton Singhavon reports

CB2 INSIGHTS APPOINTS HEALTHCARE INDUSTRY EXPERT AND FORMER IQVIA EXECUTIVE TOM BROGAN TO ITS BOARD OF DIRECTORS

CB2 Insights Inc. has appointed Tom Brogan as an independent director to CB2's board of directors. Effective immediately, Mr. Brogan will replace outgoing directors David Danziger and Gerry Goldberg who wish to pursue other opportunities. Current independent director, Norton Singhavon, has immediately been appointed interim chairman of the board.

Mr. Brogan brings 40 years experience in aggregating anonymized health care data to create insights to support traditional pharmaceutical companies and for use in health economic studies. His innovations include a long list of applications that merge real world evidence with traditional health care protocols. Mr. Brogan is currently the chief executive officer and chairman at Vestrum Health, an electronic health care record data company which delivers information systems to pharmaceutical manufacturers, physician practices and other health care stakeholders. Prior to Vestrum Health, he was the founder of Brogan Consulting, which was acquired by IMS in 2010, now IQVIA, one of the world's largest contract research organizations (CROs), following which Mr. Brogan continued on with the company as vice-president of global oncology at IMS Health.

"Mr. Brogan's extensive experience in building innovative data-driven health care technology companies combined with global operations exposure in the life sciences sector with leading names in contract research and data analytics, will be key addition to our board and leadership team, fostering the growth of CB2," said Prad Sekar, chief executive officer of CB2 Insights. "As we continue to bolster our board to be representative of the vision and direction of the company, we are confident that Mr. Brogan's track record will provide CB2 with exceptional perspective in maximizing our strategies, and exposure to traditional pharma partners for future commercialization."

"I look forward to being part of the CB2's leadership team and advising the company through the next growth phase," said Mr. Brogan. "As I have experienced before, the company's unique business strategy is proving it will a be a critical contributor to advancing the use cannabinoid-based medicines into traditional health care through technology, data and supporting clinical trials -- an area that is lacking in the current market."

"On behalf of the entire board, I would like to thank Mr. Danziger and Mr. Goldberg for their contributions to the organization," said Mr. Singhavon. "We are pleased to welcome Mr. Brogan to the board and look forward to the extensive knowledge and expertise he adds to CB2."

The company thanks Mr. Danziger and Mr. Goldberg for their contributions made during their tenures.

About CB2 Insights Inc.

CB2 Insights is a global leader in clinical operations, technology and analytics solutions, and research and development services with a mission to mainstream medical cannabis into traditional health care. Providing immediate market access through its wholly owned clinical network across 12 jurisdictions, proprietary data-driven technology solutions and comprehensive contract research services designed for those in both the medical cannabis and traditional life sciences industries, CB2 Insights is able to support its partners across the entire data and research spectrum.

We seek Safe Harbor.